Pharmacogenomics

Social, Ethical, and Clinical Dimensions

Buch | Hardcover

368 Seiten

2003
Wiley-Liss Inc.,U.S. (Verlag)
978-0-471-22769-4 (ISBN)

Artikel merken

This book examines the ethical, legal, and social implication of pharmacogenomics. Through analyses of the complex underlying issues, this interdisciplinary volume frames the agenda for dealing with genetic variation and incorporating pharmacogenomics into health care.

Through analyses of the complex underlying issues, this interdisciplinary volume frames the agenda for dealing with genetic variation and incorporating pharmacogenomics into health care. The three sections of this book, Research Issues, Clinical Issues, and Social Perspectives address key elements integral to a comprehensive discussion of this emerging field. This groundbreaking text…

Examines new research strategies, methodologies, and ethical and social considerations of pharmacogenomics
Addresses practical considerations of anticipated changes in education, training, oversight, guidelines and protocols, and continuing education requirements
Provides analyses of the potential enormous impact of pharmacogenomics, such as in the standard of care and treatment, including perspectives from the fields of anthropology, law, ethics, and economics

Mark A. Rothstein holds the Herbert F. Boehl Chair of Law and Medicine and is Director of the Institute for Bioethics, Health Policy and Law at the University of Louisville. He has appointments in the Departments of Medicine and Family and Community Medicine at the School of Medicine and at the Louis D. Brandeis School of Law. Professor Rothstein is a leading authority on genetics, privacy, and health policy. He has served as an advisor to the NIH, CDC, DOE, Institute of Medicine, National Conference of State Legislatures, and numerous other public and professional entitles.

Foreword (F. Collins). Preface.

PART I: INTRODUCTION: SCIENCE AND SOCIETY.

Public Attitudes About Pharmacogenomics (M. Rothstein, et al.).

Pharmacogenomics: Pharmacology and Toxicology in the Genomics (H. Mohrenweiser).

The Implications of Population Genetics for Pharmacogenomics (C. Hanis).

PART II: RESEARCH AND DEVELOPMENT CHALLENGES AND CONSIDERATIONS.

Genome Research and Minorities (H. Greely).

Drug Development Strategies (P. Manasco & T. Arledge).

Drug Development, Regulation, and Genetically Guided Therapy Pharmacogenomics (D. Feigal & S. Gutman).

Intellectual Property and Commercial Aspects of Pharmacogenomics (A. Nunnally, et al.).

PART III: CLINICAL APPLICATIONS.

Integration of Pharmacogenomics into Medical Practice (G. Omenn & A. Motulsky).

Clinical Utility Pharmacogenetics and Pharmacogenomics (N. Holtzman).

Medical Liability for Pharmacogenomics (L. Palmer).

The Challenges of Pharmacogenomics for Pharmacy Education, Practice, and Regulation (D. Brushwood).

PART IV: THE SOCIAL DIMENSION.

Economic Implications of Pharmacogenomics (C. Reeder & W. Dickson).

Pharmacogenomics and the Social Construction of Identity (M. Foster).

Pharmacogenomics: Considerations for Communities of Color (L. Nsiah-Jefferson).

Constitutional Issues in the Use of Pharmacogenomic Variations Associated with Race (J. Robertson).

PART V: EPILOGUE: POLICY PRESCRIPTIONS (M. Rothstein).

Pharmacogenomics and Minority Populations: General Population Survey Questionnaire (M. Rothstein).

Index.

Erscheint lt. Verlag	30.1.2003
Zusatzinfo	Drawings: 15 B&W, 0 Color; Tables: 8 B&W, 0 Color
Verlagsort	New York
Sprache	englisch
Maße	163 x 246 mm
Gewicht	653 g
Einbandart	gebunden
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
	Studium ► 2. Studienabschnitt (Klinik) ► Humangenetik
	Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie
ISBN-10	0-471-22769-2 / 0471227692
ISBN-13	978-0-471-22769-4 / 9780471227694
Zustand	Neuware